Table S1.
Excluded medications prior to visit 1
| Medication |
|---|
| Depot corticosteroids |
| Systemic, oral or parenteral corticosteroidsa |
| ICS/LABA combination products |
| Use of ICS at a dose >1,000 μg/day of fluticasone propionate or equivalent |
| Initiation or discontinuation of ICS use |
| Phosphodiesterase 4 inhibitors (roflumilast) |
| LAMAs (tiotropium, aclidinium, glycopyrronium, umeclidinium) |
| Inhaled LABAs (salmeterol, formoterol, indacaterol, vilanterol) |
| LAMA/LABA combination products |
| Theophyllines |
| Oral β2 -agonists |
| Inhaled short-acting β2 -agonistsb |
| Inhaled short-acting anticholinergics |
| Inhaled short-acting anticholinergic/short-acting β2 -agonist combination products |
| Any other investigational medication |
Notes:
a
Except for the treatment of COPD exacerbations during the study, which did not exceed 14 days. Localized corticosteroid injections were permitted.
b
Use of study-provided albuterol was permitted during the study, except in the 4-hour period prior to spirometry testing.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.